TY - JOUR
T1 - Neurological symptoms in individuals with fibrodysplasia ossificans progressiva
AU - Kitterman, Joseph A.
AU - Strober, Jonathan B.
AU - Kan, Lixin
AU - Rocke, David M.
AU - Cali, Amanda
AU - Peeper, Jeannie
AU - Snow, Jennifer
AU - Delai, Patricia L.R.
AU - Morhart, Rolf
AU - Pignolo, Robert J.
AU - Shore, Eileen M.
AU - Kaplan, Frederick S.
N1 - Funding Information:
The authors thank the FOP patients and their families who participated in this study, and the staff members of the IFOPA who provided assistance with the study. This study was supported in part by the International Fibrodysplasia Ossificans Progressiva Association, the Center for Research in FOP and Related Disorders, the Ian Cali Endowment for FOP Research, the Whitney Weldon Endowment for FOP Research, the Isaac and Rose Nassau Professorship of Orthopaedic Molecular Medicine (to FSK), the Penn Center for Musculoskeletal Disorders, and the National Institutes of Health (NIH R01-AR41916).
PY - 2012/12
Y1 - 2012/12
N2 - Fibrodysplasia ossificans progressiva (FOP), a rare, disabling condition caused by gain-of-function mutations of a bone morphogenetic protein (BMP) type I receptor, leads to episodes of heterotopic ossification and resultant immobility. Neurological problems have not been associated with FOP, but neurological symptoms are commonly reported by FOP patients. To determine the prevalence of neurological symptoms and their characteristics in individuals with FOP, we conducted a survey of the 470 patient members of the International FOP Association (IFOPA) using a questionnaire about neurological symptoms. There were 168 responses (105 females, 63 males; age 1.5-68 years) from 30 countries representing 36 % of IFOPA members. Chronic neurological symptoms were reported by 86 (51 %). Prevalence of neuropathic pain (NP) was significantly increased (P<0.001) compared to the general population, and tenfold more common in females (15 %) than males (1.6 %). Of those with NP, 94 % reported other sensory abnormalities. Prevalence of recurrent severe headaches (HA) (26 %) was similar to that in the general population, but prevalence in females with FOP (36 %) was almost fourfold greater than in males. Prevalence of NP, HA, and other sensory abnormalities was substantially higher in post-pubertal females; 33 % reported symptoms worsened during menstrual periods. Worsening of neurological symptoms during FOP flare-ups was reported by 23 %. Three patients with FOP (1.8 %) reported myoclonus, a prevalencemuch greater than reported in the general population (P<0.001). Our worldwide survey indicates that neurological symptoms are common in FOP. We speculate that these symptoms are related to effects of dysregulated BMP signaling on the central and/or peripheral nervous systems.
AB - Fibrodysplasia ossificans progressiva (FOP), a rare, disabling condition caused by gain-of-function mutations of a bone morphogenetic protein (BMP) type I receptor, leads to episodes of heterotopic ossification and resultant immobility. Neurological problems have not been associated with FOP, but neurological symptoms are commonly reported by FOP patients. To determine the prevalence of neurological symptoms and their characteristics in individuals with FOP, we conducted a survey of the 470 patient members of the International FOP Association (IFOPA) using a questionnaire about neurological symptoms. There were 168 responses (105 females, 63 males; age 1.5-68 years) from 30 countries representing 36 % of IFOPA members. Chronic neurological symptoms were reported by 86 (51 %). Prevalence of neuropathic pain (NP) was significantly increased (P<0.001) compared to the general population, and tenfold more common in females (15 %) than males (1.6 %). Of those with NP, 94 % reported other sensory abnormalities. Prevalence of recurrent severe headaches (HA) (26 %) was similar to that in the general population, but prevalence in females with FOP (36 %) was almost fourfold greater than in males. Prevalence of NP, HA, and other sensory abnormalities was substantially higher in post-pubertal females; 33 % reported symptoms worsened during menstrual periods. Worsening of neurological symptoms during FOP flare-ups was reported by 23 %. Three patients with FOP (1.8 %) reported myoclonus, a prevalencemuch greater than reported in the general population (P<0.001). Our worldwide survey indicates that neurological symptoms are common in FOP. We speculate that these symptoms are related to effects of dysregulated BMP signaling on the central and/or peripheral nervous systems.
KW - ACVR1
KW - Bone morphogenetic protein 4
KW - Substance P
UR - http://www.scopus.com/inward/record.url?scp=84872113693&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84872113693&partnerID=8YFLogxK
U2 - 10.1007/s00415-012-6562-y
DO - 10.1007/s00415-012-6562-y
M3 - Article
C2 - 22752062
AN - SCOPUS:84872113693
SN - 0340-5354
VL - 259
SP - 2636
EP - 2643
JO - Journal of Neurology
JF - Journal of Neurology
IS - 12
ER -